Patricia Judson, MD

Where You Are:

Patricia Judson, MD

Gynecologic Oncology

For Consultation Requests or Referrals: (888) 860-2778


          •  Obstetrics & Gynecology - Gynecologic Oncology

          •  University of North Carolina, Chapel Hill - Gynecologic Oncology

          •  University of California, San Francisco - Obstetrics and Gynecology

          •  University of Minnesota School of Medicine - MD

  • Sawah EA, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Zgheib NB, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL. The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest. J Cancer Res Clin Oncol. 2014 Aug. Pubmedid: 25164128.

  • Donovan KA, Boyington AR, Judson PL, Wyman JF. Bladder and bowel symptoms in cervical and endometrial cancer survivors. Psychooncology. 2014 Jun;23(6):672-678. Pubmedid: 24481859. Pmcid: PMC4043946.

  • Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep. 2014 Jan;31(1):376-383. Pubmedid: 24220856. Pmcid: PMC3981115.

  • Marchion DC, Xiong Y, Chon HS, Sawah EA, Zgheib NB, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16. Pubmedid: 23933223. Pmcid: PMC3840156.

  • Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Zgheib NB, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecol Oncol. 2013 Oct;131(1):207-212. Pubmedid: 23877012.

  • Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol. 2013 Jul;130(1):19-24. Pubmedid: 23623830.

  • Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol. 2013 Jun;208(6):501.e1-501.e7. Pubmedid: 23507546.

  • Marchion DC, Bicaku E, Xiong Y, Zgheib NB, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-2018. Pubmedid: 23467907.

  • Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS, Carson LF, Ivy JJ, Judson PL. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol. 2013 Apr;129(1):81-85. Pubmedid: 23352917.

  • Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol. 2013 Feb;128(2):155-159. Pubmedid: 23201592. Pmcid: PMC3638213.

  • Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012 Nov;30(31):3786-3791. Pubmedid: 22753905. Pmcid: PMC3478573.

  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul;22(6):960-967. Pubmedid: 22740002. Pmcid: PMC4036555.

  • Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Jul;41(1):179-188. Pubmedid: 22552627. Pmcid: PMC4017641.

  • Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Brit J Cancer. 2012 Jun;106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.

  • Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun;30(17):2039-2045. Pubmedid: 22529265. Pmcid: PMC3646321.

  • Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo J, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner PC, McMeekin DS, Darcy K, Ali S, Judson PL, Mannel RS, Lele SB, O'Malley DM, Goodfellow PJ. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila). 2012 Mar;5(3):435-443. Pubmedid: 22246618. Pmcid: PMC3294192.

  • Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan;124(1):119-124. Pubmedid: 22032837.

  • Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012 Jan;23(1):35-42. Pubmedid: 22355465. Pmcid: PMC3280065.

  • Judson PL, Dickson EL, Argenta PA, Xiong Y, Geller MA, Carson LF, Ghebre R, Jonson AL, Downs LS. A prospective, randomized trial of integrative medicine for women with ovarian cancer. Gynecol Oncol. 2011 Nov;123(2):346-350. Pubmedid: 21864886. Pmcid: PMC3393038.

  • Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct;17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.

  • Sueblinvong T, Judson PL, Downs LS, Argenta PA. Solitary fibrous tumors arising from the female pelvis. Obstet Gynecol. 2011 Aug;118(2 Pt 2):470-474. Pubmedid: 21768857.

  • Geller MA, Ivy JJ, Ghebre R, Downs LS, Judson PL, Carson LF, Jonson AL, Dusenbery K, Vogel RI, Boente MP, Argenta PA. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011 Apr;121(1):112-117. Pubmedid: 21239048.

  • Downs LS, Chura JC, Argenta PA, Judson PL, Ghebre R, Geller MA, Carson LF. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial. Gynecol Oncol. 2011 Feb;120(2):265-269. Pubmedid: 21145100.

  • Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011 Jan;13(1):98-107. Pubmedid: 20849361. Pmcid: PMC3760671.

  • Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immun. 2010 Dec;59(12):1877-1884. Pubmedid: 20820775. Pmcid: PMC4098785.

  • Geller MA, Downs LS, Judson PL, Ghebre R, Argenta PA, Carson LF, Jonson AL, Godfrey K, Vogel RI, Petzel SV. Learning about ovarian cancer at the time of diagnosis: video versus usual care. Gynecol Oncol. 2010 Nov;119(2):370-375. Pubmedid: 20673972.

  • Judson PL, Ivy JJ, Zwolak P, Manivel JC, Clohisy DR. A suspicious vulvar mass diagnosed as a subpubic cartilaginous cyst. Arch Gynecol Obstet. 2009 Jul;280(1):107-109. Pubmedid: 19031079.

  • Lanneau GS, Argenta PA, Lanneau MS, Riffenburgh RH, Gold MA, McMeekin DS, Webster N, Judson PL. Vulvar cancer in young women: demographic features and outcome evaluation. Am J Obstet Gynecol. 2009 Jun;200(6):645.e1-645.e5. Pubmedid: 19286150.

  • Argenta PA, Thomas SG, Judson PL, Downs LS, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009 May;113(2):205-209. Pubmedid: 19239974.

  • Geller MA, Argenta PA, Thomas SG, Dusenbery KE, Judson PL, Boente MP. Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies. Eur J Obstet Gynecol Reprod Biol. 2009 Apr;143(2):93-97. Pubmedid: 19195764.

  • Zins AM, Thomas SG, Judson PL, Geller MA. Intussusception caused by metastatic cervical cancer. Int J Gynaecol Obstet. 2008 Dec;103(3):262-263. Pubmedid: 18755455.

  • Downs LS, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer. 2008 Jan;112(2):331-339. Pubmedid: 18058810.

  • Argenta PA, Ormsby RR, Downs LS, Judson PL, Ghebre R, Carson LF. Routine pelvic examination during front-line chemotherapy for ovarian cancer: should it play a role?. J Reprod Med. 2008 Jan;53(1):3-7. Pubmedid: 18251353.

  • Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS. CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res. 2007 Dec;67(23):11202-11208. Pubmedid: 18056445.

  • Chura JC, Van Iseghem K, Downs LS, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007 Nov;107(2):326-330. Pubmedid: 17706754.

  • Goudge CS, Downs LS, Judson PL, Argenta PA. Stage II squamous cell carcinoma of the vagina in a patient with Bloom syndrome: a case report. J Reprod Med. 2007 Jun;52(6):557-559. Pubmedid: 17694984.

  • Chura JC, Truskinovsky AM, Judson PL, Johnson L, Geller MA, Downs LS. Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review. Gynecol Oncol. 2007 Jan;104(1):247-252. Pubmedid: 17126891.

  • Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006 May;107(5):1018-1022. Pubmedid: 16648405.

  • Argenta PA, Ghebre R, Dusenbery KE, Chen MD, Judson PL, Downs LS, Carson LF. Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. Eur J Gynaecol Oncol. 2006 Mar;27(3):231-235. Pubmedid: 16800247.

  • Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol. 2006 Mar;100(3):561-564. Pubmedid: 16271748.

  • Marushin R, Judson PL, Downs LS, Argenta PA. A large endometrioma in a patient with Turner's syndrome: a case report and review of the literature. J Pelvic Med Surg. 2006;12(5):281-285.

  • Mitchell SK, Carson LF, Judson P, Downs LS. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):793-798. Pubmedid: 16174226.

  • Dusenbery KE, Potish RA, Argenta PA, Judson PL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol. 2005 Jun;28(3):295-300. Pubmedid: 15923804.

  • Argenta PA, Kubicek GJ, Dusenberry KE, Judson PL, Downs LS, Carson LF, Boente MP. Widespread lymph node metastases in a young woman with FIGO stage IA1 squamous cervical cancer. Gynecol Oncol. 2005 May;97(2):659-661. Pubmedid: 15863175.

  • Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS, Judson PL, Carson LF, Boente MP. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol. 2004 Dec;95(3):632-636. Pubmedid: 15581975.

  • Downs LS, Judson PL, Argenta PA, Carson LF, Boente MP. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer. Gynecol Oncol. 2004 Nov;95(2):347-351. Pubmedid: 15491756.

  • Judson PL, Jonson AL, Paley PJ, Bliss RL, Murray KP, Downs LS, Boente MP, Argenta PA, Carson LF. A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. Gynecol Oncol. 2004 Oct;95(1):226-230. Pubmedid: 15385136.

  • Dusenbery KE, Potish RA, Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol. 2004 Jul;94(1):191-196. Pubmedid: 15262141.

  • Judson PL, Blair Harkness C, Boente MP, Downs LS, Argenta PA, Carson LF. A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2004 Jun;93(3):667-670. Pubmedid: 15196862.

  • Mitchell SK, Carson LF, Judson PL, Downs LS. Persistent ovarian endometrial stromal sarcoma. Oncol Nurs Forum. 2004;31(3):513-514.

  • Judson PL, Geller MA, Bliss RL, Boente MP, Downs LS, Argenta PA, Carson LF. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003 Nov;91(2):389-394. Pubmedid: 14599871.

  • Kimerling R, Rellini A, Kelly V, Judson PL, Learman L. Gender differences in victim and crime characteristics of sexual assaults at an urban rape treatment center. J Interpers Violence. 2002;17(5):526-532.

  • Judson PL, Temple AM, Fowler WC, Novotny DB, Funkhouser WK. Vaginal adenosarcoma arising from endometriosis. Gynecol Oncol. 2000 Jan;76(1):123-125. Pubmedid: 10620454.

  • Judson PL, He X, Cance WG, Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer. 1999 Oct;86(8):1551-1556. Pubmedid: 10526262.

  • Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res. 1999 May;59(10):2425-2432. Pubmedid: 10344753.

  • Korn AP, Judson PL, Zaloudek CJ. Importance of atypical glandular cells of uncertain significance in cervical cytologic smears. J Reprod Med. 1998 Sep;43(9):774-778. Pubmedid: 9777615.

  • Judson PL, Van LL. Familial breast and ovarian cancer: the role of the BRCA genes. Prim Care Update OB/Gyn. 1998;5(3):140-143.

  • Judson PL, Van Le L. Familial breast cancer and ovarian cancer: the role of BRCA genes. Prim Care Update Ob Gyns. 1998;5(3):140-143.

  • Korn AP, Judson PL, Zaloudek CJ. Importance of atypical glandular cells of uncertain significance on papanicolaou smears. J Reprod Med. 1998;43:774-778.

  • Judson PL, Van LL. Flow cytometry for obstetricians and gynecologists,. Prim Care Update OB/Gyn. 1997;4:87-91.

  • Judson PL, Van Le L. Flow cytometry for obstetricians and gynecologists. Prim Care Update Ob Gyns. 1997;4:87-91.

Dr. Patricia Judson is a gynecological oncologist in the Center for Women’s Oncology at Moffitt and an associate professor at the University of South Florida College of Medicine.  She specializes in surgical and chemotherapeutic treatments for gynecologic (GYN) malignancies.

Dr. Judson has a particular interest in minimally invasive surgery, integrative medicine and therapeutic clinical trials.  She serves on the national Gynecological Oncology Group Scientific Advisory Committee and is a principal investigator for numerous research studies.  In addition, she completed postgraduate acupuncture physicians training and conducts research on how complementary and alternative therapies affect the outcome for GYN cancer.

A graduate of the University of Minnesota School of Medicine, Dr. Judson completed a residency in obstetrics and gynecology at the University of California, San Francisco, and a fellowship in gynecological oncology at the University of North Carolina, Chapel Hill.  

Before coming to Moffitt, Dr. Judson was a tenured associate professor at the University of Minnesota, where she also served as director of the gynecological oncology fellowship program and was a Sime research fellow at the Center for Spirituality and Healing. 

Dr. Judson has received numerous national awards, including America’s Top Obstetricians and Gynecologists Consumer’s Award by the Research Council of America, Best Doctors in America® and “Top Doctors” by the Minneapolis St. Paul Magazine.


TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions